Role of leucine-rich α-2-glycoprotein in Taiwanese patients with inflammatory bowel disease as a predictive biomarker for endoscopic activity

Table 1 Clinical characteristics of patients with inflammatory bowel disease, n (%)

	UC (n = 100)	CD (n = 103)
Male sex	54 (54.0)	69 (67.0)
Age (years old), median (IQR)	50 (40-61)	43 (33-56)
Time interval, day, median (IQR)1	11.5 (3-24)	15.5 (6.5-24)
Disease extent
E1	2 (2.0)	-
E2	16 (16.0)	-
E3	82 (82.0)	-
L1	-	2 (1.9)
L2	-	11 (10.7)
L3	-	90 (87.4)
Upper GI modifier	-	5 (4.9)
Perianal disease modifier	-	14 (13.6)
Laboratory data, median (IQR)
Hb (g/dL)	13.5 (12.5-14.5)	13.9 (12.6-15)
Alb (g/dL)	4.5 (4.3-4.7)	4.5 (4.4-4.8)
CRP (mg/dL)	0.1 (0.05-0.23)	0.11 (0.05-0.33)
LRG (μg/mL)	8.6 (7.05-11.1)	9.0 (6.9-12.1)
FC (mg/kg)	47.5 (17-230)	68 (32-257)
Endoscopic activity
MES < 2	51 (51)	-
MES ≥ 2	49 (49)	-
SES-CD < 6	-	76 (73.8)
SES-CD ≥ 6	-	27 (26.2)
Clinical disease activity, median (IQR)
Partial Mayo score	0 (0-1)	-
HBI	-	1 (0-2)
Medications
No current therapies	3 (3.0)	8 (7.8)
5-ASA	91 (91.0)	15 (14.6)
Immunomodulators	16 (16.0)	57 (55.3)
Corticosteroid	9 (9.0)	3 (2.9)
Biologics
Anti-TNF	2 (2.0)	40 (38.8)
Anti-integrin	17 (17.0)	5 (4.9)
Anti-IL12/23 or anti-IL23	5 (5.0)	19 (18.4)
JAK inhibitor	9 (9.0)	1 (1.0)

¹Time interval (days) between endoscopy and laboratory tests.

UC: Ulcerative colitis; CD: Crohn’s disease; IQR: Interquartile range; E1: Proctitis; E2: Left-sided; E3: Extensive disease; L1: Ileal; L2: Colonic; L3: Ileocolonic; GI: Gastrointestinal; Hb: Hemoglobin; Alb: Albumin; CRP: C-reactive protein; LRG: Leucine-rich α-2-glycoprotein; FC: Fecal calprotectin; MES: Mayo endoscopic subscore; SES-CD: Simple Endoscopic Score for Crohn’s disease; HBI: Harvey-Bradshaw index; 5-ASA: 5-aminosalicylic acid; TNF: Tumor necrosis factor; IL: Interleukin; JAK: Janus kinase.